Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma

(2022) Samuel Chuah et al.   JOURNAL OF HEPATOLOGY

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

(2022) Andrew X. Zhu et al.   NATURE MEDICINE

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

(2022) Tae Kon Kim et al.   NATURE REVIEWS DRUG DISCOVERY

Advances in immunotherapy for hepatocellular carcinoma

(2021) Bruno Sangro et al.   Nature Reviews Gastroenterology & Hepatology

A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

(2021) Weiqin Yang et al.   Science Translational Medicine

Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

(2021) Chia-Lang Hsu et al.   Liver Cancer

From bench to bedside: Single-cell analysis for cancer immunotherapy

(2021) Emily F. Davis-Marcisak et al.   CANCER CELL

S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation

(2021) Shuangqing Liu et al.   Journal for ImmunoTherapy of Cancer

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer

(2021) Chewei Anderson Chang et al.   Cancer Discovery

Top 10 Challenges in Cancer Immunotherapy

(2020) Priti S. Hegde et al.   IMMUNITY

A molecular switch regulating transcriptional repression and activation of PPARγ

(2020) Jinsai Shang et al.   Nature Communications

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

(2020) David A. Braun et al.   NATURE MEDICINE

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer

(2020) Yann Kieffer et al.   Cancer Discovery

Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

(2020) Matthias Pinter et al.   GUT

The role of Peroxisome Proliferator-Activated Receptors (PPAR) in immune responses

(2020) Anthos Christofides et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice

(2019) Liang Wen et al.   HEPATOLOGY

Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma

(2019) Man Liu et al.   GUT

The pan‐cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia

(2019) Wai Hoong Chang et al.   Annals of the New York Academy of Sciences

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer

(2019) Lichun Ma et al.   CANCER CELL

Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma

(2019) Qiming Zhang et al.   CELL

The great escape: tumour cell plasticity in resistance to targeted therapy

(2019) Soufiane Boumahdi et al.   NATURE REVIEWS DRUG DISCOVERY

Unravelling cellular relationships during development and regeneration using genetic lineage tracing

(2019) Chloé S. Baron et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers

(2019) Chang Gon Kim et al.   Science Immunology

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization

(2018) Fei Zhao et al.   IMMUNITY

Hepatocellular carcinoma

(2018) Alejandro Forner et al.   LANCET

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

ImmPort, toward repurposing of open access immunological assay data for translational and clinical research

(2018) Sanchita Bhattacharya et al.   Scientific Data

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer

(2018) Bogang Wu et al.   OncoImmunology

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

(2018) Hanjie Li et al.   CELL

Altered cancer metabolism in mechanisms of immunotherapy resistance

(2018) Rishab Ramapriyan et al.   PHARMACOLOGY & THERAPEUTICS

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy

(2017) Jingying Zhou et al.   GUT

Translational Implications of Tumor Heterogeneity

(2015) M. Jamal-Hanjani et al.   CLINICAL CANCER RESEARCH

The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications

(2015) Bénédicte Delire et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

(2015) Sven Francque et al.   JOURNAL OF HEPATOLOGY

Metabolic functions of FABPs—mechanisms and therapeutic implications

(2015) Gökhan S. Hotamisligil et al.   Nature Reviews Endocrinology

Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro

(2010) Jun Yu et al.   HEPATOLOGY